Recent Combination Approval: CheckMate-9LA Regimen


Stephen Liu, MD: The CheckMate 9LA regimen is the most recent regimen that was added to our treatment arsenal. This was the first time in my knowledge that we had approval of the drug before we see any of the data. This is a combination of platinum doublet chemotherapy, histology specific, combined with dual-checkpoint blockade using the PD-1 inhibitor nivolumab and the CTLA4 inhibitor ipilimumab. The unique wrinkle here is that chemotherapy was given only with the first 2 cycles, not the first 4, and there was no indefinite maintenance chemotherapy.

The rationale and strategy is to provide a means to get that initial rapid cytotoxic control, to avoid that initial drop in PFS [progression-free survival] to provide that benefit for patients with aggressive disease or high burden of disease and facilitate an initial response. Then, toward the cycles beyond the second round, to lean more on that dual-checkpoint blockade for durable benefit and for more meaningful duration of response. When we look at the outcome from this phase 3 registrational trial, over 700 patients randomized, there was a survival benefit. Now, it’s important to look at the patient characteristics. About 30% were squamous, a little different from studies like KEYNOTE-024, where it was closer to 20%. If you look at the PD-L1 breakdown, we would typically expect about a third negative, a third positive low, and a third positive high. Here it was about 40% PD-L1 negative, so you just want to keep those populations in mind when we look at absolute numbers.

It was a randomized trial. Compared with chemotherapy alone, the chemotherapy–nivo-ipi [nivolumab-ipilimumab] approach did provide a survival benefit. Overall survival was 15.6 months versus 10.9 months with a hazard ratio of 0.66. The 1-year survival rate was 63% compared with 47% with chemotherapy. Broken down by histology in the nonsquamous group, we saw 17-month OS versus 11.9, hazard ratio of 0.69. In the squamous, 14.5 months versus 9.1, hazard ratio of 0.62. In both squamous and nonsquamous histologies, really across PD-L1 subsets, the addition of nivo-ipi [nivolumab-ipilimumab] to 2 cycles of chemotherapy provided a clear benefit over chemotherapy alone. The control arms didn’t necessarily underperform. If we look at the PD-L1–negative group, the survival hazard ratio was 0.62. In the PD-L1–high group, 0.66, which is remarkably similar across. One-year survival rates across PD-L1 subsets were 60% to 70%. We also saw the PFS benefit, 6.7 months with nivo-ipi [nivolumab-ipilimumab]–chemotherapy versus 5 months with chemotherapy alone with a hazard ratio of 0.68. When we look at those Kaplan-Meier curves for PFS, and we don’t see that initial drop. We don’t see that crossing of the early curves, just 2 cycles of chemotherapy preventing benefit. Some propose that may be countering hyperprogression, but in any case we see the favorable early benefit from adding chemotherapy in that long-term tail with a dual-checkpoint blockade.

Neal E. Ready, MD: I’m going to talk about CheckMate 9LA. While CheckMate 227 was a long time coming and it took awhile to have approval for nivolumab and ipilimumab on the CheckMate 227 regimen, 9LA came on us all of a sudden. CheckMate 9LA was a randomized phase 3 trial for all-histology lung cancer, and the control arm was standard histology-based chemotherapy. The experimental arm was nivolumab and low-dose ipilimumab regimen from CheckMate 227 plus 2 cycles of chemotherapy.

The reason for the 2 cycles of chemotherapy is that with immunotherapy, sometimes we will see early progression. That’s particularly a concern in patients who have a high tumor volume or are symptomatic from their cancer, so this regimen gave only 2 cycles of chemotherapy. To prevent early progression, avoid long-duration toxicity from chemotherapy, then also provide the double immunotherapy for a chance for a higher number of immune responses that will give us a really long duration of benefit, a long-term benefit of 3, 4, and 5 years.

In this trial, the 9LA regimen was positive. It was superior to chemotherapy, and it was superior for overall survival, progression-free survival, and overall response rate. The duration of response was better for those who responded to treatment, and progression-free survival was better for the 9LA regimen compared with the chemotherapy.

For 9LA, the primary end point was overall survival compared with chemotherapy for all PD-L1 types. The FDA approval for the 9LA regimen is for any PD-L1 type, positive or negative, in non–small cell lung cancer.

The CheckMate 9LA regimen was unique in that it looked to give some chemotherapy at the beginning to avoid early progression of the cancer but minimize the exposure to chemotherapy toxicity, so only 2 cycles of chemotherapy were given. This is the period where in immunotherapy-alone trials we will sometimes see rapid progression of the cancer and in which the immunotherapy arm looks inferior to the chemotherapy arm.

I think this 9LA strategy with 2 cycles of chemotherapy was successful. We can look at the progression-free survival curve, and early on the nivo-ipi [nivolumab-ipilimumab]–containing arm was not inferior to the standard chemotherapy arm, but we gave the chemotherapy for only 2 cycles. And we don’t see as much cumulative grade 3 and 4 toxicity that we see in some of the chemotherapy doublet trials, where patients receive a standard course of chemotherapy plus a new therapy. The strategy for 9LA was successful, and it minimized the exposure of chemotherapy but prevented the early progression that we sometimes see with immunotherapy alone.

Transcript Edited for Clarity

Related Videos
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Saad J. Kenderian, MB, CHB
Jaime Schneider, MD, PhD
Benjamin Creelan, MD
Neel P. Chudgar, MD
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine
Raj Singh, MD
Arya Amini, MD